205 related articles for article (PubMed ID: 30340483)
1. Timeline representation of clinical data: usability and added value for pharmacovigilance.
Ledieu T; Bouzillé G; Thiessard F; Berquet K; Van Hille P; Renault E; Polard E; Cuggia M
BMC Med Inform Decis Mak; 2018 Oct; 18(1):86. PubMed ID: 30340483
[TBL] [Abstract][Full Text] [Related]
2. The quality of spontaneous adverse drug reaction reports from the pharmacovigilance centre in western China.
Niu R; Xiang Y; Wu T; Zhang Z; Chen Y; Feng B
Expert Opin Drug Saf; 2019 Jan; 18(1):51-58. PubMed ID: 30574811
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
4. Clinical Data Analytics With Time-Related Graphical User Interfaces: Application to Pharmacovigilance.
Ledieu T; Bouzillé G; Polard E; Plaisant C; Thiessard F; Cuggia M
Front Pharmacol; 2018; 9():717. PubMed ID: 30233354
[TBL] [Abstract][Full Text] [Related]
5. Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study.
Durrieu G; Jacquot J; Mège M; Bondon-Guitton E; Rousseau V; Montastruc F; Montastruc JL
Drug Saf; 2016 Dec; 39(12):1189-1195. PubMed ID: 27688025
[TBL] [Abstract][Full Text] [Related]
6. Adverse drug reaction reporting in institutions across six Chinese provinces: a cross-sectional study.
Zhang X; Niu R; Feng B; Guo J; Liu Y; Liu X
Expert Opin Drug Saf; 2019 Jan; 18(1):59-68. PubMed ID: 29883236
[TBL] [Abstract][Full Text] [Related]
7. First experiences with a tool to measure the level of clinical information present in adverse drug reaction reports.
Oosterhuis I; Rolfes L; Ekhart C; Muller-Hansma A; Härmark L
Expert Opin Drug Saf; 2018 Feb; 17(2):111-115. PubMed ID: 29157026
[TBL] [Abstract][Full Text] [Related]
8. Harnessing scientific literature reports for pharmacovigilance. Prototype software analytical tool development and usability testing.
Sorbello A; Ripple A; Tonning J; Munoz M; Hasan R; Ly T; Francis H; Bodenreider O
Appl Clin Inform; 2017 Mar; 8(1):291-305. PubMed ID: 28326432
[TBL] [Abstract][Full Text] [Related]
9. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
Tandon VR; Mahajan V; Khajuria V; Gillani Z
Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
[TBL] [Abstract][Full Text] [Related]
10. Enhancing Pediatric Adverse Drug Reaction Documentation in the Electronic Medical Record.
Tillman EM; Suppes SL; Feldman K; Goldman JL
J Clin Pharmacol; 2021 Feb; 61(2):181-186. PubMed ID: 32776356
[TBL] [Abstract][Full Text] [Related]
11. Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia-a restraint to the potentiality for signal detection.
Plessis L; Gómez A; García N; Cereza G; Figueras A
Eur J Clin Pharmacol; 2017 Jun; 73(6):751-758. PubMed ID: 28251276
[TBL] [Abstract][Full Text] [Related]
12. The adverse drug reaction reporting assignment for specialist oncology nurses: a preliminary evaluation of quality, relevance and educational value in a prospective cohort study.
Schutte T; van Eekeren R; Richir M; van Staveren J; van Puijenbroek E; Tichelaar J; van Agtmael M
Naunyn Schmiedebergs Arch Pharmacol; 2018 Jan; 391(1):17-26. PubMed ID: 29063137
[TBL] [Abstract][Full Text] [Related]
13. The contribution of Ghanaian patients to the reporting of adverse drug reactions: a quantitative and qualitative study.
Jacobs TG; Hilda Ampadu H; Hoekman J; Dodoo ANO; Mantel-Teeuwisse AK
BMC Public Health; 2018 Dec; 18(1):1384. PubMed ID: 30563498
[TBL] [Abstract][Full Text] [Related]
14. Drug safety and big clinical data: Detection of drug-induced anaphylactic shock events.
Bouzillé G; Osmont MN; Triquet L; Grabar N; Rochefort-Morel C; Chazard E; Polard E; Cuggia M
J Eval Clin Pract; 2018 Jun; 24(3):536-544. PubMed ID: 29532572
[TBL] [Abstract][Full Text] [Related]
15. The EU-ADR Web Platform: delivering advanced pharmacovigilance tools.
Oliveira JL; Lopes P; Nunes T; Campos D; Boyer S; Ahlberg E; van Mulligen EM; Kors JA; Singh B; Furlong LI; Sanz F; Bauer-Mehren A; Carrascosa MC; Mestres J; Avillach P; Diallo G; Díaz Acedo C; van der Lei J
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):459-67. PubMed ID: 23208789
[TBL] [Abstract][Full Text] [Related]
16. A tailor-made approach for causality assessment for ADR reports on drugs and vaccines.
Oosterhuis I; Zweers P; Rümke H; Muller-Hansma A; van Puijenbroek EP
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):544-550. PubMed ID: 30168222
[TBL] [Abstract][Full Text] [Related]
17. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center.
Abadie D; Chebane L; Bert M; Durrieu G; Montastruc JL
Therapie; 2014; 69(5):395-400. PubMed ID: 25269141
[TBL] [Abstract][Full Text] [Related]
18. The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015.
van Hunsel F; de Waal S; Härmark L
Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):977-983. PubMed ID: 28524293
[TBL] [Abstract][Full Text] [Related]
19. [Completeness of pharmacovigilance reporting in general medicine in France.].
Humbert X; Jacquot J; Alexandre J; Sassier M; Robin N; Pageot C; Kheloufi F; Joyau C; Coquerel A; Durrieu G; Fedrizzi S
Sante Publique; 2019; Vol. 31(4):561-566. PubMed ID: 31959257
[TBL] [Abstract][Full Text] [Related]
20. Causality assessment of adverse drug reaction reports using an expert-defined Bayesian network.
Rodrigues PP; Ferreira-Santos D; Silva A; Polónia J; Ribeiro-Vaz I
Artif Intell Med; 2018 Sep; 91():12-22. PubMed ID: 30077492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
